An analysis on the new treatment strategy targeting histone-modification for the tumor-initiating cells of esophageal squamous cell carcinoma
Project/Area Number |
26861061
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Digestive surgery
|
Research Institution | Chiba University |
Principal Investigator |
|
Project Period (FY) |
2014-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Keywords | 食道扁平上皮癌 / 癌幹細胞 / エピジェネティクス |
Outline of Final Research Achievements |
Esophageal squamous cell carcinoma (ESCC) is one of the highly malignant cancers with poor prognosis. To improve the prognosis of advanced ESCC, the development of novel and potent chemotherapeutic agent is expected. In recent years, the existence of tumor-initiating cells and their treatment-resistance have been noted in gastrointestinal cancer. It is thought that tumor-initiating cells are major contributors to cancer relapse, and removing the tumor-initiating cells might improve the radical cure rate. However, there have been only a few reports on the tumor-initiating cells of ESCC. Here we confirmed that ALDH1 positive cells concentrated into the spheres derived from the ESCC cell line. Further the clinicopathological study was performed and the group with high expression level of ALDH1 had a trend toward worse survival compared with those with lower ALDH1. It was suggested that ALDH1 was one of the useful ESCC tumor-initiating cell markers.
|
Report
(3 results)
Research Products
(4 results)